Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Vivodyne, a biotech startup focused on replacing animal testing in drug development by using AI and robotic technology to grow human tissues in the lab, has raised $40 million in a Series A funding round. This latest investment brings the company’s total funding to $78 million. The funding comes amid a broader shift as the FDA and NIH move away from animal testing. Separately, Tevogen has announced a collaboration with Microsoft and Databricks to enhance its ExacTcell technology using artificial intelligence, including plans to expand its AI team headquarters.
Vivodyne, which uses AI and robots to grow human tissues in the lab for drug discovery and development, raised a $40M Series A, taking its total funding to $78M (@katmdavis / Axios) https://t.co/9nFzzFfKEp https://t.co/U87bdWWGpZ https://t.co/ZOzeer1FAj
Vivodyne lands $40m to replace animal testing in drug development #longevity #biotech #investment #drugdevelopment https://t.co/CjIcDkXtuj https://t.co/B4GsG0aGiN
Just in: Tevogen $TVGN unveils https://t.co/zCJZucJgax initiative with Microsoft $MSFT and Databricks, aiming to enhance its ExacTcell tech with AI. The move includes expanding HQ for the AI team. #AI #Biotech